Huadong pharmaceutical plans to transfer 5.2 million 3 traditional Chinese medicine varieties

In the evening of August 6, East China Pharmaceutical announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (hereinafter referred to as "Zhongmei Huadong"), the holding subsidiary of the company, planned to invest 52 million yuan to transfer the three traditional Chinese medicine varieties of Suzhou Yusen new drug development Co., Ltd (hereinafter referred to as "Suzhou Yusen") In the long run, the sales of the three kinds of products are expected to exceed 200 million yuan, according to brokers The announcement indicates that China and the United States intend to invest 52 million yuan in Suzhou province to receive the new medicine technology of Shen Li Xin granule, Yin Shen Granule and Yin Hu rectal gel, which are owned by Yu sen in Among them, Shen Li Xin and Yin Hu rectal gel are the two clinical results, with the price being 15 million yuan and 12 million yuan respectively , priced at 25 million yuan The announcement didn't introduce the specific situation of the three varieties On August 7, the reporter called the Securities Department of the company, and the other side replied, "what was released yesterday evening is just an instant announcement At present, we are concentrating on preparing the relevant issues of the announcement of the China news In a few days, the company will issue another announcement to introduce the specific situation of the three varieties of traditional Chinese medicine in detail." According to the event comment issued by Xingye securities in August 7th, the above three varieties are all 6 kinds of new drugs of Chinese medicine Among them, the silver ginseng granule, which has been approved by production, has the effects of Invigorating Qi, activating blood circulation, eliminating phlegm and dredging collaterals, and can be used for treatment of coronary heart disease and angina pectoris Shen Lixin granule and silver Hu valence rectal gel are obtained in 2008 and 2004 respectively, and two varieties are about to end two Stage clinical, respectively for the treatment of chronic nephritis and asthma in children Societe Generale Securities expects that two varieties of Shen Lixin granule and silver price rectal gel are expected to get a new drug certificate in 2016 Societe Generale Securities believes that in the long run, the sales of the above three traditional Chinese medicine varieties are expected to exceed 200 million yuan If they can enter the national medical insurance catalog, there will be more space Industrial Securities also pointed out that if Shenlixin granules are approved, the marketing channel of Bailing capsule, the company's heavyweight product, can be used Bailing capsule is the most important product in the medical and pharmaceutical sector of East China Its main function is "invigorating the lung and kidney, benefiting the essence and Qi" After rapid growth in recent years, its sales volume in 2012 was about 800 million yuan In 2012, the company's pharmaceutical sector achieved a total revenue of 1.75 billion yuan In 2012, the company's revenue was 14.579 billion yuan, a year-on-year increase of 31%; the net profit attributable to the listed company was 470 million yuan, a year-on-year increase of 23% On August 7, the company closed up 2.93% at yuan.